Data_Sheet_1_Association of Serum miR-186-5p With the Prognosis of Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention.zip

Circulating miR-186-5p is an emerging biomarker for acute coronary syndrome (ACS) patients. However, its kinetic signatures and prognostic values in ACS patients undergoing percutaneous coronary intervention (PCI) remain unclear. Levels of serum miR-186-5p were determined in 96 healthy controls and 92 ACS patients before and after PCI by qRT-PCR, and the physiologic state of miR-186-5p was analyzed by comparing its absolute concentrations in isolated exosomes and exosome-depleted supernatants. An average of 1 year of follow-up for ACS patients after PCI was performed. MiR-186-5p levels in the myocardium and serum of rats following left anterior descending coronary artery (LAD) ligation were measured. Serum miR-186-5p levels were found to be significantly increased in ACS patients upon admission compared with those of controls, but these high miR-186-5p levels gradually decreased within 1 week after PCI. Serum miR-186-5p was mainly present in an exosome-free form rather than membrane-bound exosomes. Within 1 year of follow-up, ACS patients with higher miR-186-5p levels upon admission exhibited a higher incidence of MACE after PCI. Different statistical analyzes further validated the independent prognostic values of serum miR-186-5p in ACS patients after PCI. Serum miR-186-5p levels in rats following LAD ligation were increased, and there was a decrease in myocardial miR-186-5p levels. Kyoto encyclopedia of genes and genomes (KEGG) analysis was performed to predict the related pathways of target genes of miR-186-5p, which suggested that miR-186-5p might be involved in ACS by regulating the inflammatory status and D-glucose metabolism. In conclusion, a distinctive expression signature of serum miR-186-5p may contribute to monitoring the clinical condition and assessing the prognosis of ACS patients undergoing PCI.

循环miR-186-5p作为一种新兴的生物标志物，在急性冠状动脉综合征（ACS）患者中具有重要意义。然而，其在ACS患者接受经皮冠状动脉介入治疗（PCI）过程中的动力学特征及其预后价值尚不明确。研究通过定量逆转录聚合酶链反应（qRT-PCR）技术，对96名健康对照者和92名ACS患者在PCI前后血清miR-186-5p水平进行了测定，并通过对分离的囊泡及其去囊泡上清液中miR-186-5p的绝对浓度进行比较，分析了miR-186-5p的生理状态。对PCI术后ACS患者进行了平均1年的随访。在LAD结扎后，测量了大鼠心肌和血清中的miR-186-5p水平。入院时，与对照者相比，ACS患者的血清miR-186-5p水平显著升高，但PCI术后1周内这些高水平的miR-186-5p逐渐降低。血清miR-186-5p主要以无囊泡形式存在，而非膜结合的囊泡形式。在1年的随访期内，入院时miR-186-5p水平较高的ACS患者，PCI术后主要不良心血管事件（MACE）的发生率更高。不同的统计分析进一步验证了血清miR-186-5p在PCI术后ACS患者中的独立预后价值。在LAD结扎后的大鼠血清miR-186-5p水平升高，而心肌miR-186-5p水平下降。通过京都基因与基因组百科全书（KEGG）分析预测miR-186-5p靶基因的相关通路，表明miR-186-5p可能通过调节炎症状态和D-葡萄糖代谢参与ACS。综上所述，血清miR-186-5p的独特表达特征可能有助于监测PCI术后ACS患者的临床状况和评估其预后。